Search results
Results from the WOW.Com Content Network
Surgical risk, age, perceived life expectancy, and valve durability influence the choice between surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation. The contemporaneous life expectancy after SAVR, in relation to surgical risk and age, is unknown.
Transcatheter aortic valve replacement (TAVR) may reduce symptoms of aortic valve stenosis. Fewer symptoms may help improve quality of life. Following a heart-healthy lifestyle is important as you recover from TAVR .
Based on the simulation model, the durability of TAVR valves must be 70% shorter than that of surgical valves to result in reduced life expectancy in older low-risk patients. The threshold for TAVR device durability was substantially higher in younger low-risk patients.
From April 2008 to December 2020, a total of 991 patients with symptomatic severe aortic stenosis underwent TAVR with balloon-expandable or self-expanding valves were included. Primary outcomes and survival analysed on base to age <75 years and ≥75 years old.
Transcatheter aortic valve replacement (TAVR) becomes the leading therapeutic choice for severe aortic stenosis. There is a growing body of knowledge on long-term survival outcomes, but available data from real-world observational studies are scarce.
This data suggests that a 42-year-old patient undergoing aortic valve replacement (AVR) with a tissue valve is expected to live to 58 years of age. In contrast, a 42-year-old in the general population is expected to live to 78 years of age.
The aortic valve is the most common valve requiring replacement among people older than 65, when calcium deposits are more likely to build up on the heart valves. “Severe aortic stenosis is a life-limiting condition—median survival is only about two years,” says Dr. Vora.
A transcatheter aortic valve replacement (TAVR) procedure replaces a damaged aortic valve with a new one. TAVR is minimally invasive and may improve quality of life.
Recent clinical trial results showed that transcatheter aortic valve replacement (TAVR) is noninferior and may be superior to surgical aortic valve replacement (SAVR) for mortality, stroke, and rehospitalization. However, the impact of transcatheter valve durability remains uncertain.
Contemporary data on loss in life expectancy after aortic valve replacement (AVR) are scarce, particularly in younger patients. The purpose of this national, observational cohort study was to analyze long-term relative survival and estimated loss in life expectancy after AVR.